Literature DB >> 9069459

A case of renal amyloidosis associated with hepatic adenoma: the pathogenetic role of tumor necrosis factor-alpha.

T Shibasaki1, H Matsumoto, K Watabe, K Joh, H Nakano, H Matsuda, H Gomi, I Ohno, F Ishimoto, O Sakai.   

Abstract

We report a case of a 35-year-old man with secondary amyloidosis chiefly involving the kidney and heart. The patient showed severe proteinuria and ischemic heart damage and had hepatic adenoma at the age of 33. Biopsy specimens from the kidney, heart, stomach and rectum showed extensive deposition of amyloid. After the surgical resection of a 300-gram hepatic adenoma, highly elevated c-reactive protein (CRP) levels decreased and the serum amyloid A (SAA) level was completely normalized. Normal liver cells were immunostained with rabbit anti-SAA antibody, but the cells in adenoma tissue and kidney were not. Electron microscopic examination revealed extracellular deposition of amyloid fibrils in the hepatic adenoma and kidney tissue. The concentration of tumor necrosis factor-alpha (TNF-alpha) (312 pg/mg tissue protein) was 7-fold higher in adenoma tissue than in normal liver tissue. Moreover, SAA (2.8 ng/mg tissue protein) was 2-fold higher in normal liver tissue than in adenoma tissue. Since TNF-alpha has been known to induce SAA production in target cells, the present results suggest that the hepatic adenoma produced TNF-alpha, which then caused mainly secondary amyloidosis in the kidney and heart. Currently, 2 years after surgical resection, urinary excretion of protein has been markedly reduced (from 3.5 to 0.8 g/day) and renal and cardiac functions are normal without specific medical treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9069459     DOI: 10.1159/000189560

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  5 in total

1.  Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management.

Authors:  A Sa Cunha; J F Blanc; E Lazaro; L Mellottee; B Le Bail; J Zucman-Rossi; C Balabaud; P Bioulac-Sage
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

2.  Etanercept therapy in patients with advanced primary amyloidosis.

Authors:  M A Hussein; J V Juturi; L Rybicki; S Lutton; B R Murphy; M A Karam
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

3.  Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients.

Authors:  Senol Kobak; Fahrettin Oksel; Yasemin Kabasakal; Eker Doganavsargil
Journal:  Clin Rheumatol       Date:  2007-07-05       Impact factor: 2.980

4.  AA Amyloidosis in a patient with glycogen storage disorder and progressive chronic kidney disease.

Authors:  Jonathan Dick; Nicola Kumar; Catherine Horsfield; Satish Jayawardene
Journal:  Clin Kidney J       Date:  2012-11-04

5.  Obesity-induced chronic inflammation in high fat diet challenged C57BL/6J mice is associated with acceleration of age-dependent renal amyloidosis.

Authors:  Roel A van der Heijden; Johan Bijzet; Wouter C Meijers; Gopala K Yakala; Robert Kleemann; Tri Q Nguyen; Rudolf A de Boer; Casper G Schalkwijk; Bouke P C Hazenberg; Uwe J F Tietge; Peter Heeringa
Journal:  Sci Rep       Date:  2015-11-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.